Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Primary Peritoneal Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00055705
What this trial is testing

PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer

Who this might be right for
Cancer
Memorial Sloan Kettering Cancer Center
Not applicableNot Yet RecruitingNCT07687602
What this trial is testing

Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting

Who this might be right for
Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian CancerFolate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube CancerFolate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer
AbbVie
Early research (Phase 1)Ended earlyNCT02452775
What this trial is testing

Autologous OC-L Vaccine and Ovarian Cancer

Who this might be right for
Primary Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Abramson Cancer Center at Penn Medicine 3
Testing effectiveness (Phase 2)Study completedNCT01899599
What this trial is testing

PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer

Who this might be right for
Ovarian Epithelial Cancer RecurrentFallopian Tube CancerPrimary Peritoneal Cancer
Glycotope GmbH 216
Testing effectiveness (Phase 2)Active Not RecruitingNCT03587311
What this trial is testing

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous AdenocarcinomaOvarian Endometrioid Adenocarcinoma+5 more
National Cancer Institute (NCI) 96
Testing effectiveness (Phase 2)Active Not RecruitingNCT03579316
What this trial is testing

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
M.D. Anderson Cancer Center 96
Early research (Phase 1)Active Not RecruitingNCT04616534
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Who this might be right for
Advanced Fallopian Tube CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma+19 more
National Cancer Institute (NCI) 14
Large-scale testing (Phase 3)Not Yet RecruitingNCT07797283
What this trial is testing

Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1

Who this might be right for
Ovarian Cancer
Incyte Corporation 590
Early research (Phase 1)Study completedNCT00989651
What this trial is testing

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Fallopian Tube CarcinomaFallopian Tube CarcinosarcomaFallopian Tube Clear Cell Adenocarcinoma+35 more
National Cancer Institute (NCI) 431
Early research (Phase 1)Study completedNCT03508570
What this trial is testing

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Who this might be right for
Malignant Peritoneal NeoplasmMalignant Retroperitoneal NeoplasmMetastatic Cervical Carcinoma+31 more
M.D. Anderson Cancer Center 26
Early research (Phase 1)Active Not RecruitingNCT05277766
What this trial is testing

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

Who this might be right for
Peritoneal CarcinomatosisPeritoneal MetastasesColorectal Cancer+5 more
University Hospital, Ghent 45
Not applicableEnded earlyNCT03412630
What this trial is testing

Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
ECOG-ACRIN Cancer Research Group 1
Testing effectiveness (Phase 2)Study completedNCT00182767
What this trial is testing

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

Who this might be right for
Fallopian Tube CancerFemale Reproductive CancerRecurrent Breast Cancer+4 more
National Cancer Institute (NCI) 45
Testing effectiveness (Phase 2)Study completedNCT02606305
What this trial is testing

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Epithelial Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
ImmunoGen, Inc. 264
Testing effectiveness (Phase 2)Study completedNCT04387227
What this trial is testing

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
University of Washington 22
Testing effectiveness (Phase 2)Study completedNCT01720173
What this trial is testing

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Gynecologic Oncology Group 30
Testing effectiveness (Phase 2)Study completedNCT00671788
What this trial is testing

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Gynecologic Oncology Group 35
Large-scale testing (Phase 3)Ended earlyNCT01281254
What this trial is testing

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
Amgen 223
Testing effectiveness (Phase 2)Study completedNCT00063401
What this trial is testing

Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Who this might be right for
Ovarian CancerPeritoneal NeoplasmsFallopian Tube Neoplasms
Eli Lilly and Company 39
Testing effectiveness (Phase 2)Study completedNCT03126812
What this trial is testing

Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer

Who this might be right for
Ovarian Cancer Stage IVPeritoneal CancerFallopian Tube Cancer
The Netherlands Cancer Institute 33
Next Page
69